ClouDr (9955.HK) Signs Service Cooperation Agreement with JD Health (6618.HK) for Online Pharmaceutical Expansion

Bulletin Express

昨天

ClouDr (9955.HK) has announced a service cooperation agreement with JD Health (6618.HK) to expand online sales and service channels for Remifemin® and other P2M pipeline products. The arrangement aims to offer a more convenient purchasing experience and comprehensive health management support.

JD Health, as a significant pharmaceutical e-commerce platform with a substantial user base, is expected to bolster the reach of ClouDr’s cost-effective medications. ClouDr’s expertise in chronic disease management and unique product pipeline will, in turn, contribute to more efficient patient-doctor interaction and product promotion.

The Board of ClouDr confirms that JD Health is an independent third party. ClouDr intends to comply with relevant regulatory requirements in this cooperation process, cautioning shareholders and potential investors to exercise due care when trading its securities. The agreement was officially announced on November 13, 2025.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/1151645734"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"1151645734\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/1151645734?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-11-13 12:23","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1151645734","market":"us","top_or_hot":-1,"title":"ClouDr (9955.HK) Signs Service Cooperation Agreement with JD Health (6618.HK) for Online Pharmaceutical Expansion","media":"Bulletin Express","content":"<p>ClouDr (9955.HK) has announced a service cooperation agreement with JD Health (6618.HK) to expand online sales and service channels for Remifemin® and other P2M pipeline products. The arrangement aims to offer a more convenient purchasing experience and comprehensive health management support.</p>\n<p>JD Health, as a significant pharmaceutical e-commerce platform with a substantial user base, is expected to bolster the reach of ClouDr’s cost-effective medications. ClouDr’s expertise in chronic disease management and unique product pipeline will, in turn, contribute to more efficient patient-doctor interaction and product promotion.</p>\n<p>The Board of ClouDr confirms that JD Health is an independent third party. ClouDr intends to comply with relevant regulatory requirements in this cooperation process, cautioning shareholders and potential investors to exercise due care when trading its securities. The agreement was officially announced on November 13, 2025.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ClouDr (9955.HK) Signs Service Cooperation Agreement with JD Health (6618.HK) for Online Pharmaceutical Expansion</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nClouDr (9955.HK) Signs Service Cooperation Agreement with JD Health (6618.HK) for Online Pharmaceutical Expansion\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time smaller\">2025-11-13 12:23</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<p>ClouDr (9955.HK) has announced a service cooperation agreement with JD Health (6618.HK) to expand online sales and service channels for Remifemin® and other P2M pipeline products. The arrangement aims to offer a more convenient purchasing experience and comprehensive health management support.</p>\n<p>JD Health, as a significant pharmaceutical e-commerce platform with a substantial user base, is expected to bolster the reach of ClouDr’s cost-effective medications. ClouDr’s expertise in chronic disease management and unique product pipeline will, in turn, contribute to more efficient patient-doctor interaction and product promotion.</p>\n<p>The Board of ClouDr confirms that JD Health is an independent third party. ClouDr intends to comply with relevant regulatory requirements in this cooperation process, cautioning shareholders and potential investors to exercise due care when trading its securities. The agreement was officially announced on November 13, 2025.</p>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"09955","symbol_name":"智雲健康","start_time":0,"source_url":"","article_id":"1151645734","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1151645734","pubTimestamp":1763007793,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"ClouDr (9955.HK) has announced a service cooperation agreement with JD Health (6618.HK) to expand online sales and service channels for Remifemin® and other P2M pipeline products. The arrangement...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"09955":"智云健康"},"translate_title":"ClouDr(9955.HK)与京东健康(6618.HK)签署在线医药扩张服务合作协议","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"09955":1},"content_text":"ClouDr (9955.HK) has announced a service cooperation agreement with JD Health (6618.HK) to expand online sales and service channels for Remifemin® and other P2M pipeline products. The arrangement aims to offer a more convenient purchasing experience and comprehensive health management support.\nJD Health, as a significant pharmaceutical e-commerce platform with a substantial user base, is expected to bolster the reach of ClouDr’s cost-effective medications. ClouDr’s expertise in chronic disease management and unique product pipeline will, in turn, contribute to more efficient patient-doctor interaction and product promotion.\nThe Board of ClouDr confirms that JD Health is an independent third party. ClouDr intends to comply with relevant regulatory requirements in this cooperation process, cautioning shareholders and potential investors to exercise due care when trading its securities. The agreement was officially announced on November 13, 2025.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"corporation,SGX","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}